

Subject, city, state	Effective date	Subject, city, state	Effective date	Subject, city, state	Effective date
N OLMSTED, OH		OMAHA, NE		OCONOMOWOL, WI	
DEFAULT ON HEAL LOAN		MONICA, JULIANNE H	02/20/2002		
ALEXANDER, MICHAEL A	02/20/2002	SPRING LAKE, NJ		Dated: March 4, 2002.	
ALQUIPPA, PA		NEWELL, DAVID CLIFFORD ...	02/20/2002	Calvin Anderson, Jr.,	
ARGUEDAS, WALTER G	02/20/2002	FORT BRAGG, CA		<i>Director, Health Care Administrative</i>	
HIALEAH, FL		OWGZAREK, KEITH VINCENT	02/20/2002	<i>Sanctions, Office of Inspector General.</i>	
BELLER, BRYAN D	02/20/2002	MARYSVILLE, WA		[FR Doc. 02-5944 Filed 3-12-02; 8:45 am]	
SOUTHGATE, MI		PATT, RICHARD H	02/20/2002	BILLING CODE 4150-04-P	
CAFAGNA, MARK WILLIAM		NEW YORK, NY			
SR	02/20/2002	PEISS, STUART	02/20/2002		
WEST HILLS, CA		HOFFMAN ESTATES, IL			
CAGLE, LARRY S	02/20/2002	PHILLIPS, THADDEUS		DEPARTMENT OF HEALTH AND	
AHOSKIE, NC		HILLARD III	02/20/2002	HUMAN SERVICES	
CARR, GUY A	02/20/2002	SAN ANTONIO, TX		National Institutes of Health	
HUTCHINSON, KS		PORTNOW, ROBERT THOMAS	02/20/2002	Proposed Collection; Comment	
CONSTANTINESCU, SERBAN		AS	02/20/2002	Request; Policies of Academic	
CRISTIA	02/20/2002	CLEVELAND, OH		Institutions Regarding Tobacco	
PHILADELPHIA, PA		RAMU, NALAYA	02/20/2002	Industry Research Funding	
COOPER, SHIRLEY T	02/20/2002	LOS ANGELES, CA		SUMMARY: In compliance with the	
LANSDALE, PA		RASHTI, KOUROS	02/20/2002	requirement of Section 3506(c)(2)(A) of	
CRAIG, BRADLEY D	02/20/2002	TARZANA, CA		the Paperwork Reduction Act of 1995,	
SNOWFLAKE, AZ		RICHBERG, MARK H	02/20/2002	for opportunity for public comment on	
DE JESUS-MIRANDA, LUIS A		PHILADELPHIA, PA	02/20/2002	proposed data collection projects, the	
SAN JUAN, PR		RIGNEY, MARK EDWARD	02/20/2002	national Cancer Institute (NCI), the	
DIENER, ROBERT B	02/20/2002	OKLAHOMA CITY, OK		National Institutes of Health (NIH) will	
AUBURNDALE, MA		ROMERO, JOHN JOSEPH	02/20/2002	publish periodic summaries of proposed	
DONELSON, RICHARD BAR-		ALBURQUERQUE, NM	02/20/2002	projects to be submitted to the Office of	
TON	02/20/2002	RORRER, MARK TIMOTHY ...	02/20/2002	Management and Budget (OMB) for	
PHOENIX, AZ		CLAYTON, OH		review and approval.	
EATON, GARY D	02/20/2002	ROZENBERG, RONALD L	02/20/2002	Proposed Collection	
SPRINGFIELD, MO		LEVITTOWN, NY		<i>Title:</i> Policies of Academic	
ELLZEY, PAUL D	02/20/2002	RUSSELL, BILL	02/20/2002	Institutions Regarding Tobacco Industry	
PRATTVILLE, AL		ST LOUIS, MO		Research Funding.	
FISHBOUGH, ROSS E	02/20/2002	SAID, SAED M	12/18/2001	<i>Type of Information Collection</i>	
BENSLAEM, PA		DUNIONVILLE, CT		<i>Request:</i> NEW.	
FLOYD, THOMAS PARKER ...	02/20/2002	SANDOR, GEORGE JOSEPH	02/20/2002	<i>Need and Use of Information</i>	
TRUFANT, MI		NEW YORK, NY		<i>Collection:</i> This study will assess	
GREETHONG, KITIMAN	02/20/2002	SAUTMAN, SATPAL K	02/20/2002	current administrative policies of	
IRVINE, CA		PLANTATION, FL		medical schools and schools of public	
HAGEN, CALVIN P	02/20/2002	SCHWARTZ, FRANCIS XA-	02/20/2002	health regarding faculty acceptance of	
KANSAS CITY, MO		VIER JR	02/20/2002	research funding from tobacco	
HANSEN, KRIS T	02/20/2002	OAKLAND, CA		manufacturers and trade organizations.	
ST GEORGE, UT		SCHWARZ-MANDRACCHIA,	02/20/2002	The primary objectives of the study are	
HORNIG-ROHAN, JAMES ED-		DENISE MA	02/20/2002	to assess how many institutions have a	
WARD	02/20/2002	WINTERSET, IA		tobacco-specific research funding	
SENECA, SC		SLOTNICK, ROBIN T	02/20/2002	policy, their reasons for adopting or not	
IBRIK, AMIR	02/20/2002	CLEVELAND, OH		adopting such a policy, and what the	
SYRACUSE, NY		STOCK, ANN M	02/20/2002	requirements of those policies are. The	
KALMAN, BETSY S	02/20/2002	BELLEVILLE, IL		finding will provide valuable	
RICHMOND HILL, NY		THOMPSON, JANETTE A	02/20/2002	information concerning: (1) How	
KRUGMAN, LINDA L	02/20/2002	SILVER SPRING, MD		academic institutions have responded to	
LEXINGTON, KY		TOLIVER, EDWARD C	02/20/2002	concerns about researchers' funding	
LE SAGE, SAHARA ADAMS ...	02/20/2002	CHICAGO, IL		relationships in tobacco research, (2)	
LEAGUE CITY, TX		VESTICH, GEORGE T	02/20/2002	administrators' attitudes towards	
LEONELLI, DAVID ROMAN SR		RICHMOND, OH	02/20/2002	research funding policies targeted at	
LOS ANGELES, CA		VILLANO, GUY JOHN	02/20/2002	tobacco specifically; and (3) what types	
LEWIS, STEVEN R	02/20/2002	NISKAYUNA, NY		of requirements have been imposed on	
IRVING, TX		WALCHER, KEVIN RAY	02/20/2002	academic researchers regarding tobacco	
LINSTEADT, ELIZABETH M ...	02/20/2002	BOOKER, TX		funding.	
DENISON, TX		WALTERS, BRIAN D JR	02/20/2002	<i>Frequency of Response:</i> Once.	
LUCEY, TIMOTHY D	02/20/2002	SEATTLE, WA		<i>Affected Public:</i> Individuals;	
NEWBURGH, NY		WAN, JAMES Y	02/20/2002	academic institutions.	
MARTINEZ, DANIEL A	02/20/2002	MOBILE, AL		<i>Type of Respondents:</i> academic	
REDLANDS, CA		WHEDBEE, JOSEPH IRE-	02/20/2002	administrators.	
MASSAKOWSKI, EDWARD A		LAND	02/20/2002		
BENSALEM, PA		REDLANDS, CA			
MCGHEE, STEPHANIE Y	02/20/2002	WILLIAMS, ERIC A	02/20/2002		
HOUSTON, TX		TOWSON, MD			
MCINNES, THOMAS K	02/20/2002	WILSON, RONALD E	02/20/2002		
POOLESVILLE, MD		DETROIT, MI			
MEINHOLD, STEVEN DALE ...	02/20/2002	YODER, KYLE JAY	02/20/2002		
		REDWOOD CITY, CA			
		ZIMMERMAN, MARY L P	02/20/2002		

The annual reporting burden is as follows:

Estimated Number of Respondents: 156.

Estimated Number of Responses per Respondent: 1.

Average Burden Hours Per Response: .5.

Estimated Total Annual Burden Hours Requested: 78.

The annualized cost to respondents is estimated at: \$780. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Mark Parascandola, Cancer Prevention Fellow, OPO, DCP, NCI, NIH, 6130 Executive Boulevard, Suite 3109, Bethesda, MD 20892, or call non-toll-free number (301) 594-1576 or E-mail your request, including your address to: paramark@mail.nih.gov.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before May 13, 2002.

Dated: February 19, 2002.

Reesa L. Nichols,

NCI Project Clearance Liaison.

[FR Doc. 02-5930 Filed 3-12-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Artificial Chromosomes That Can Shuttle Between Bacteria, Yeast, and Mammalian Cells

Larionov et al. (NCI)

DHHS Reference No. E-253-00/0 filed April 6, 2001

Licensing Contact: Pradeep Ghosh; 301/496-7736 ext. 211; e-mail ghoshp@od.nih.gov.

Development of a novel cloning system in mammalian cells based on Mammalian Artificial Chromosome (MAC) may have profound effects on human gene therapy. The technology described in invention pertains to methods and compositions that allow for the selective isolation of centromeric regions from mammalian chromosomes, including those of humans. Also included in the invention are cloned and characterized centromeric regions of humans and other mammalian chromosomes. The isolation of these centromeric regions provides a material for engineering of MACs that are capable of being shuttled between bacterial, yeast and mammalian cells, such as human cells. These MACs may serve as effective tools for the characterization of cis-active loci controlling transmission of mammalian

chromosomes. The present invention has broad utilities in studies related to genetic diseases. It can be used for studying of expression of entire copies of human genes. Gene therapy may have therapeutic and preventative applications and a range of gene therapy approaches are currently being evaluated for treatment of cancer and a large number of autoimmune and genetic disorders. Gene therapy necessitates an efficient system for gene delivery. The MACs constructed in this invention provide useful vehicles for the delivery and expression of transgenes within cells. Thus, the present invention provides a novel method allowing a direct isolation of mammalian centromeres and efficient system for gene delivery associated with gene therapy.

Treatment of Pain Based on Parathyroid Hormone-2 (PTH2) Receptors

Ted B. Usdin (NIMH)

DHHS Reference No. E-079-01/0 filed Jun 13 2001

Licensing Contact: Norbert Pontzer; 301/496-7736 ext. 284; e-mail: np59n@nih.gov.

Current medications for pain, especially chronic pain, are only partially effective and can involve unacceptable side effects. A unique receptor (PTH2) and an endogenous ligand (TIP39) which binds to the receptor were previously discovered by this inventor. The PTH2 receptor and the endogenous ligand were found to have an anatomical distribution suggesting a role in nociception. The PTH2 receptor is present at relatively high levels in nerve terminals within the outer layers of the dorsal horn of the spinal cord where it is primarily coupled to generation of cAMP (Usdin, T.B., et al., 1999, *Nature Neurosci.* 2: 941-943; Wang, T., et al, 2000, *Neuroscience* 100: 629-49; Usdin, T.B., et al, 2000, *Front Neuroendocrinol* 21: 349-83) The DRG neurons that project to this area are largely nociceptors and this region contains the central nervous system neurons they activate. Most receptors present in the central terminals of DRG neurons are also found in their peripheral terminals. Thus, activation of the PTH2 receptor could modulate peripheral excitation of nociceptors, neurotransmitter release from their central terminals in the spinal cord, and some of their postsynaptic effects.

This inventor has now shown the PTH2 receptor system to have very potent actions in animal tests of nociception. Both peripheral and